{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [["cardiovascular disease", "celastrol", "diastolic dysfunction", "heart failure", "heart failure with preserved ejection fraction", "oxidative stress", "systems disease", "traditional Chinese medicine"]], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": [], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "34490381", "DateRevised": {"Year": "2021", "Month": "09", "Day": "08"}, "Article": {"ArticleDate": [{"Year": "2021", "Month": "08", "Day": "18"}], "Language": ["eng"], "ELocationID": ["725602", "10.3389/fcvm.2021.725602"], "Journal": {"ISSN": "2297-055X", "JournalIssue": {"Volume": "8", "PubDate": {"Year": "2021"}}, "Title": "Frontiers in cardiovascular medicine", "ISOAbbreviation": "Front Cardiovasc Med"}, "ArticleTitle": "The Potential Therapeutic Role of Celastrol in Patients With Heart Failure With Preserved Ejection Fraction.", "Pagination": {"StartPage": "725602", "MedlinePgn": "725602"}, "Abstract": {"AbstractText": ["Analysis of left ventricular systolic dysfunction remained at the centre of heart failure research for many years (also known as heart failure with reduced ejection fraction, HFrEF). Although more than 50% of all heart failure patients experience a form of heart failure characterised by preserved ejection fraction (HFpEF), the pathophysiological mechanisms leading to this form of heart failure remain not well-understood. Several evidence-based treatments for HFrEF are in routine use, but there are limited evidence-based therapies for HFpEF. The effects of these remain controversial, with current treatment options being limited to managing the associated symptoms and conditions. Accumulating evidence demonstrates that pro-inflammatory and oxidative stress pathways play key roles in the development and progression of HFpEF, such as the Unfolded Protein Response (UPR) and inducible nitric oxide synthase. Celastrol, derived from medicinal plants, is a bioactive compound with strong anti-inflammatory properties, which could deem it as fruitful in overcoming the effects of such dysregulated UPR. This literature review therefore focuses on Celastrol's anti-inflammatory and antioxidant activities, alongside its other potential therapeutic activities, and its ability to impede the pathways that are thought to be involved in the development of HFpEF, such as the JAK2/STAT pathway, to elucidate the potential therapeutic role of this bioactive compound, in the treatment of HFpEF."], "CopyrightInformation": "Copyright \u00a9 2021 Ajmal, Ajmal, Huang and Zeng."}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "GKT School of Medical Education, Faculty of Life Science and Medicine, King's College London, London, United Kingdom."}], "LastName": "Ajmal", "ForeName": "Maryam", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "St. George's Hospital Medical School, University of London, London, United Kingdom."}], "LastName": "Ajmal", "ForeName": "Aisha", "Initials": "A"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Heart Center, Tianjin Third Central Hospital, Tianjin, China."}, {"Identifier": [], "Affiliation": "Tianjin Key Laboratory of Extracorporeal Life Support for Critical Diseases, Tianjin Third Central Hospital, Tianjin, China."}], "LastName": "Huang", "ForeName": "Lei", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "School of Cardiovascular Medicine and Sciences, King's College London British Heart Foundation Centre of Excellence, Faculty of Life Science and Medicine, King's College London, London, United Kingdom."}], "LastName": "Zeng", "ForeName": "Lingfang", "Initials": "L"}], "PublicationTypeList": ["Journal Article", "Review"]}, "MedlineJournalInfo": {"Country": "Switzerland", "MedlineTA": "Front Cardiovasc Med", "NlmUniqueID": "101653388", "ISSNLinking": "2297-055X"}, "CoiStatement": "The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Coronel R, de Groot JR, van Lieshout JJ. Defining heart failure. Cardiovasc Res. (2001) 50:419\u201322. 10.1016/S0008-6363(01)00284-X", "ArticleIdList": ["10.1016/S0008-6363(01)00284-X", "11376615"]}, {"Citation": "Ponikowski P, Anker SD, AlHabib KF, Cowie MR, Force TL, Hu S, et al. . Heart failure: preventing disease and death worldwide. ESC Heart Fail. (2014) 1:4\u201325. 10.1002/ehf2.12005", "ArticleIdList": ["10.1002/ehf2.12005", "28834669"]}, {"Citation": "Mosterd A, Hoes AW. Clinical epidemiology of heart failure. Heart. (2007) 93:1137\u201346. 10.1136/hrt.2003.025270", "ArticleIdList": ["10.1136/hrt.2003.025270", "PMC1955040", "17699180"]}, {"Citation": "Grossman W. Diastolic dysfunction in congestive heart failure. N Engl J Med. (1991) 325:1557\u201364. 10.1056/NEJM199111283252206", "ArticleIdList": ["10.1056/NEJM199111283252206", "1834939"]}, {"Citation": "How to diagnose diastolic heart failure . European Study Group on Diastolic Heart Failure. Eur Heart J. (1998) 19:990\u20131003. 10.1053/euhj.1998.1057", "ArticleIdList": ["10.1053/euhj.1998.1057", "9717033"]}, {"Citation": "Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, et al. . 2016 ESC Guidelines for the diagnosis treatment of acute chronic heart failure: the Task Force for the diagnosis treatment of acute chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. (2016) 37:2129\u2013200. 10.1093/eurheartj/ehw128", "ArticleIdList": ["10.1093/eurheartj/ehw128", "27206819"]}, {"Citation": "Andronic AA, Mihaila S, Cinteza M. Heart failure with mid-range ejection fraction - a new category of heart failure or still a gray zone. Maedica (Bucur). (2016) 11:320\u20134.", "ArticleIdList": ["PMC5543525", "28828050"]}, {"Citation": "Schwarzl M, Ojeda F, Zeller T, Seiffert M, Becher PM, Munzel T, et al. . Risk factors for heart failure are associated with alterations of the LV end-diastolic pressure-volume relationship in non-heart failure individuals: data from a large-scale, population-based cohort. Eur Heart J. (2016) 37:1807\u201314. 10.1093/eurheartj/ehw120", "ArticleIdList": ["10.1093/eurheartj/ehw120", "27055814"]}, {"Citation": "Kjeldsen SE, von Lueder TG, Smiseth OA, Wachtell K, Mistry N, Westheim AS, et al. . Medical therapies for heart failure with preserved ejection fraction. Hypertension. (2020) 75:23\u201332. 10.1161/HYPERTENSIONAHA.119.14057", "ArticleIdList": ["10.1161/HYPERTENSIONAHA.119.14057", "31786973"]}, {"Citation": "van der Pol A, Gil A, Tromp J, Sillj\u00e9 HHW, van Veldhuisen DJ, Voors AA, et al. . OPLAH ablation leads to accumulation of 5-oxoproline, oxidative stress, fibrosis, and elevated fillings pressures: a murine model for heart failure with a preserved ejection fraction. Cardiovasc Res. (2018) 114:1871\u201382. 10.1093/cvr/cvy187", "ArticleIdList": ["10.1093/cvr/cvy187", "30032247"]}, {"Citation": "Zheng SL, Chan FT, Nabeebaccus AA, Shah AM, McDonagh T, Okonko DO, et al. . Drug treatment effects on outcomes in heart failure with preserved ejection fraction: a systematic review and meta-analysis. Heart. (2018) 104:407\u201315. 10.1136/heartjnl-2017-311652", "ArticleIdList": ["10.1136/heartjnl-2017-311652", "PMC5861385", "28780577"]}, {"Citation": "Desai AS, Jhund PS. After TOPCAT: what to do now in heart failure with preserved ejection fraction. Eur Heart J. (2016) 37:3135\u201340. 10.1093/eurheartj/ehw114", "ArticleIdList": ["10.1093/eurheartj/ehw114", "27075872"]}, {"Citation": "Van Tassell BW, Arena R, Biondi-Zoccai G, Canada JM, Oddi C, Abouzaki NA, et al. . Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study). Am J Cardiol. (2014) 113:321\u20137. 10.1016/j.amjcard.2013.08.047", "ArticleIdList": ["10.1016/j.amjcard.2013.08.047", "PMC4899612", "24262762"]}, {"Citation": "Eggebeen J, Kim-Shapiro DB, Haykowsky M, Morgan TM, Basu S, Brubaker P, et al. . One week of daily dosing with beetroot juice improves submaximal endurance and blood pressure in older patients with heart failure and preserved ejection fraction. JACC Heart Fail. (2016) 4:428\u201337. 10.1016/j.jchf.2015.12.013", "ArticleIdList": ["10.1016/j.jchf.2015.12.013", "PMC4892939", "26874390"]}, {"Citation": "Filippatos G, Maggioni AP, Lam CSP, Pieske-Kraigher E, Butler J, Spertus J, et al. . Patient-reported outcomes in the SOluble guanylate Cyclase stimulatoR in heArT failurE patientS with PRESERVED ejection fraction (SOCRATES-PRESERVED) study. Eur J Heart Fail. (2017) 19:782\u201391. 10.1002/ejhf.800", "ArticleIdList": ["10.1002/ejhf.800", "28586537"]}, {"Citation": "Redfield MM, Anstrom KJ, Levine JA, Koepp GA, Borlaug BA, Chen HH, et al. . Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med. (2015) 373:2314\u201324. 10.1056/NEJMoa1510774", "ArticleIdList": ["10.1056/NEJMoa1510774", "PMC4712067", "26549714"]}, {"Citation": "van Empel V, Brunner-La Rocca HP. Helping to understand heart failure with preserved ejection fraction. Eur Heart J. (2018) 39:2836\u20138. 10.1093/eurheartj/ehy368", "ArticleIdList": ["10.1093/eurheartj/ehy368", "29992303"]}, {"Citation": "Wang H, Anstrom K, Ilkayeva O, Muehlbauer MJ, Bain JR, McNulty S, et al. . Sildenafil treatment in heart failure with preserved ejection fraction: targeted metabolomic profiling in the RELAX trial. JAMA Cardiol. (2017) 2:896\u2013901. 10.1001/jamacardio.2017.1239", "ArticleIdList": ["10.1001/jamacardio.2017.1239", "PMC5815079", "28492915"]}, {"Citation": "Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, et al. . Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial. Eur J Heart Fail. (2019) 21:1279\u201387. 10.1002/ejhf.1596", "ArticleIdList": ["10.1002/ejhf.1596", "31523904"]}, {"Citation": "Lewis GA, Schelbert EB, Naish JH, Bedson E, Dodd S, Eccleson H, et al. . Pirfenidone in heart failure with preserved ejection fraction-rationale and design of the PIROUETTE trial. Cardiovasc Drugs Ther. (2019) 33:461\u201370. 10.1007/s10557-019-06876-y", "ArticleIdList": ["10.1007/s10557-019-06876-y", "PMC6689029", "31069575"]}, {"Citation": "Pfeffer MA, Shah AM, Borlaug BA. Heart failure with preserved ejection fraction in perspective. Circ Res. (2019) 124:1598\u2013617. 10.1161/CIRCRESAHA.119.313572", "ArticleIdList": ["10.1161/CIRCRESAHA.119.313572", "PMC6534165", "31120821"]}, {"Citation": "Chatfield KC, Sparagna GC, Chau S, Phillips EK, Ambardekar AV, Aftab M, et al. . Elamipretide improves mitochondrial function in the failing human heart. JACC Basic Transl Sci. (2019) 4:147\u201357. 10.1016/j.jacbts.2018.12.005", "ArticleIdList": ["10.1016/j.jacbts.2018.12.005", "PMC6488757", "31061916"]}, {"Citation": "Zhang L, Chen J, Yan L, He Q, Xie H, Chen M. Resveratrol ameliorates cardiac remodeling in a murine model of heart failure with preserved ejection fraction. Front Pharmacol. (2021) 12:646240. 10.3389/fphar.2021.646240", "ArticleIdList": ["10.3389/fphar.2021.646240", "PMC8225267", "34177571"]}, {"Citation": "Sun F, Huang Y, Li L, Wang Y, Zhuang P, Zhang Y. PKA/\u03b22-AR-Gs/Gi signaling pathway is associated with anti-inflammatory and pro-apoptotic effects of Fuzi and Banxia combination on rats subjected to pressure overload. J Ethnopharmacol. (2019) 235:375\u201384. 10.1016/j.jep.2019.02.011", "ArticleIdList": ["10.1016/j.jep.2019.02.011", "30738114"]}, {"Citation": "Zhang N, Zhao Y, Liu Y, Tang N, Zheng W, Mao M, et al. . A double-blinded, placebo-controlled randomized trial evaluating the efficacy and safety of Zhigancao Tang granules for treating HFpEF: study protocol for a randomized controlled trial. Trials. (2021) 22:293. 10.1186/s13063-021-05232-6", "ArticleIdList": ["10.1186/s13063-021-05232-6", "PMC8056488", "33879223"]}, {"Citation": "Cascao R, Fonseca JE, Moita LF. Celastrol: a spectrum of treatment opportunities in chronic diseases. Front Med (Lausanne). (2017) 4:69. 10.3389/fmed.2017.00069", "ArticleIdList": ["10.3389/fmed.2017.00069", "PMC5471334", "28664158"]}, {"Citation": "Tao X, Lipsky PE. The Chinese anti-inflammatory and immunosuppressive herbal remedy Tripterygium wilfordii Hook F. Rheum Dis Clin North Am. (2000) 26:29\u201350. 10.1016/S0889-857X(05)70118-6", "ArticleIdList": ["10.1016/S0889-857X(05)70118-6", "10680192"]}, {"Citation": "Liu J, Lee J, Salazar Hernandez MA, Mazitschek R, Ozcan U. Treatment of obesity with celastrol. Cell. (2015) 161:999\u20131011. 10.1016/j.cell.2015.05.011", "ArticleIdList": ["10.1016/j.cell.2015.05.011", "PMC4768733", "26000480"]}, {"Citation": "Xu S, Feng Y, He W, Xu W, Xu W, Yang H, et al. . Celastrol in metabolic diseases: progress and application prospects. Pharmacol Res. (2021) 167:105572. 10.1016/j.phrs.2021.105572", "ArticleIdList": ["10.1016/j.phrs.2021.105572", "33753246"]}, {"Citation": "Saito K, Davis KC, Morgan DA, Toth BA, Jiang J, Singh U, et al. . Celastrol reduces obesity in MC4R deficiency and stimulates sympathetic nerve activity affecting metabolic and cardiovascular functions. Diabetes. (2019) 68:1210\u201320. 10.2337/db18-1167", "ArticleIdList": ["10.2337/db18-1167", "PMC6610022", "30894367"]}, {"Citation": "Ye S, Luo W, Khan ZA, Wu G, Xuan L, Shan P, et al. . Celastrol attenuates angiotensin ii-induced cardiac remodeling by targeting STAT3. Circ Res. (2020) 126:1007\u201323. 10.1161/CIRCRESAHA.119.315861", "ArticleIdList": ["10.1161/CIRCRESAHA.119.315861", "32098592"]}, {"Citation": "Chamberlain AM, St Sauver JL, Gerber Y, Manemann SM, Boyd CM, Dunlay SM, et al. . Multimorbidity in heart failure: a community perspective. Am J Med. (2015) 128:38\u201345. 10.1016/j.amjmed.2014.08.024", "ArticleIdList": ["10.1016/j.amjmed.2014.08.024", "PMC4282820", "25220613"]}, {"Citation": "Rodriguez-Iturbe B, Pons H, Johnson RJ. Role of the immune system in hypertension. Physiol Rev. (2017) 97:1127\u201364. 10.1152/physrev.00031.2016", "ArticleIdList": ["10.1152/physrev.00031.2016", "PMC6151499", "28566539"]}, {"Citation": "Obokata M, Reddy YNV, Pislaru SV, Melenovsky V, Borlaug BA. Evidence supporting the existence of a distinct obese phenotype of heart failure with preserved ejection fraction. Circulation. (2017) 136:6\u201319. 10.1161/CIRCULATIONAHA.116.026807", "ArticleIdList": ["10.1161/CIRCULATIONAHA.116.026807", "PMC5501170", "28381470"]}, {"Citation": "Gladden JD, Chaanine AH, Redfield MM. Heart failure with preserved ejection fraction. Annu Rev Med. (2018) 69:65\u201379. 10.1146/annurev-med-041316-090654", "ArticleIdList": ["10.1146/annurev-med-041316-090654", "29414252"]}, {"Citation": "Mishra S, Kass DA. Cellular and molecular pathobiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. (2021) 18:400\u201323. 10.1038/s41569-020-00480-6", "ArticleIdList": ["10.1038/s41569-020-00480-6", "PMC8574228", "33432192"]}, {"Citation": "Paulus WJ, Zile MR. From systemic inflammation to myocardial fibrosis: the heart failure with preserved ejection fraction paradigm revisited. Circ Res. (2021) 128:1451\u201367. 10.1161/CIRCRESAHA.121.318159", "ArticleIdList": ["10.1161/CIRCRESAHA.121.318159", "PMC8351796", "33983831"]}, {"Citation": "Shuai W, Wen J, Li X, Wang D, Li Y, Xiang J. High-choline diet exacerbates cardiac dysfunction, fibrosis, and inflammation in a mouse model of heart failure with preserved ejection fraction. J Card Fail. (2020) 26:694\u2013702. 10.1016/j.cardfail.2020.04.017", "ArticleIdList": ["10.1016/j.cardfail.2020.04.017", "32417378"]}, {"Citation": "Collier P, Watson CJ, Voon V, Phelan D, Jan A, Mak G, et al. . Can emerging biomarkers of myocardial remodelling identify asymptomatic hypertensive patients at risk for diastolic dysfunction and diastolic heart failure? Eur J Heart Fail. (2011) 13:1087\u201395. 10.1093/eurjhf/hfr079", "ArticleIdList": ["10.1093/eurjhf/hfr079", "21719449"]}, {"Citation": "Ju SM, Youn GS, Cho YS, Choi SY, Park J. Celastrol ameliorates cytokine toxicity and pro-inflammatory immune responses by suppressing NF-kappaB activation in RINm5F beta cells. BMB Rep. (2015) 48:172\u20137. 10.5483/BMBRep.2015.48.3.147", "ArticleIdList": ["10.5483/BMBRep.2015.48.3.147", "PMC4453024", "25059279"]}, {"Citation": "Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. (2018) 122:624\u201338. 10.1161/CIRCRESAHA.117.311586", "ArticleIdList": ["10.1161/CIRCRESAHA.117.311586", "PMC5819359", "29449364"]}, {"Citation": "Ukena C, Mahfoud F, Kindermann M, Kindermann I, Bals R, Voors AA, et al. . The cardiopulmonary continuum systemic inflammation as \u2018common soil\u2019 of heart and lung disease. Int J Cardiol. (2010) 145:172\u20136. 10.1016/j.ijcard.2010.04.082", "ArticleIdList": ["10.1016/j.ijcard.2010.04.082", "20570377"]}, {"Citation": "Paulus WJ, Tsch\u00f6pe C. A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation. J Am Coll Cardiol. (2013) 62:263\u201371. 10.1016/j.jacc.2013.02.092", "ArticleIdList": ["10.1016/j.jacc.2013.02.092", "23684677"]}, {"Citation": "Zile MR, Baicu CF, Ikonomidis JS, Stroud RE, Nietert PJ, Bradshaw AD, et al. . Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. (2015) 131:1247\u201359. 10.1161/CIRCULATIONAHA.114.013215", "ArticleIdList": ["10.1161/CIRCULATIONAHA.114.013215", "PMC4390480", "25637629"]}, {"Citation": "Kenchaiah S, Ding J, Carr JJ, Allison MA, Budoff MJ, Tracy RP, et al. . Pericardial fat and the risk of heart failure. J Am Coll Cardiol. (2021) 77:2638\u201352. 10.1016/j.jacc.2021.04.003", "ArticleIdList": ["10.1016/j.jacc.2021.04.003", "PMC8218602", "34045020"]}, {"Citation": "Packer M, Kitzman DW. Obesity-related heart failure with a preserved ejection fraction: the mechanistic rationale for combining inhibitors of aldosterone, neprilysin, and sodium-glucose cotransporter-2. JACC Heart Fail. (2018) 6:633\u20139. 10.1016/j.jchf.2018.01.009", "ArticleIdList": ["10.1016/j.jchf.2018.01.009", "29525327"]}, {"Citation": "Panday A, Sahoo MK, Osorio D, Batra S. NADPH oxidases: an overview from structure to innate immunity-associated pathologies. Cell Mol Immunol. (2015) 12:5\u201323. 10.1038/cmi.2014.89", "ArticleIdList": ["10.1038/cmi.2014.89", "PMC4654378", "25263488"]}, {"Citation": "Vasan RS. Diastolic heart failure. BMJ. (2003) 327:1181\u20132. 10.1136/bmj.327.7425.1181", "ArticleIdList": ["10.1136/bmj.327.7425.1181", "PMC274046", "14630731"]}, {"Citation": "Moris D, Spartalis M, Spartalis E, Karachaliou GS, Karaolanis GI, Tsourouflis G, et al. . The role of reactive oxygen species in the pathophysiology of cardiovascular diseases and the clinical significance of myocardial redox. Ann Transl Med. (2017) 5:326. 10.21037/atm.2017.06.27", "ArticleIdList": ["10.21037/atm.2017.06.27", "PMC5566734", "28861423"]}, {"Citation": "Johar S, Cave AC, Narayanapanicker A, Grieve DJ, Shah AM. Aldosterone mediates angiotensin II-induced interstitial cardiac fibrosis via a Nox2-containing NADPH oxidase. FASEB J. (2006) 20:1546\u20138. 10.1096/fj.05-4642fje", "ArticleIdList": ["10.1096/fj.05-4642fje", "16720735"]}, {"Citation": "Touyz RM, Briones AM, Sedeek M, Burger D, Montezano AC. NOX isoforms and reactive oxygen species in vascular health. Mol Interv. (2011) 11:27\u201335. 10.1124/mi.11.1.5", "ArticleIdList": ["10.1124/mi.11.1.5", "21441119"]}, {"Citation": "Cross AR, Segal AW. The NADPH oxidase of professional phagocytes\u2013prototype of the NOX electron transport chain systems. Biochim Biophys Acta. (2004) 1657:1\u201322. 10.1016/j.bbabio.2004.03.008", "ArticleIdList": ["10.1016/j.bbabio.2004.03.008", "PMC2636547", "15238208"]}, {"Citation": "Manea A. NADPH oxidase-derived reactive oxygen species: involvement in vascular physiology and pathology. Cell Tissue Res. (2010) 342:325\u201339. 10.1007/s00441-010-1060-y", "ArticleIdList": ["10.1007/s00441-010-1060-y", "21052718"]}, {"Citation": "Riehle C, Bauersachs J. Key inflammatory mechanisms underlying heart failure. Herz. (2019) 44:96\u2013106. 10.1007/s00059-019-4785-8", "ArticleIdList": ["10.1007/s00059-019-4785-8", "PMC6439138", "30715565"]}, {"Citation": "Kakishita M, Nakamura K, Asanuma M, Morita H, Saito H, Kusano K, et al. . Direct evidence for increased hydroxyl radicals in angiotensin II-induced cardiac hypertrophy through angiotensin II type 1a receptor. J Cardiovasc Pharmacol. (2003) 42(Suppl. 1):S67\u201370. 10.1097/00005344-200312001-00015", "ArticleIdList": ["10.1097/00005344-200312001-00015", "14871032"]}, {"Citation": "Cameron VA, Mocatta TJ, Pilbrow AP, Frampton CM, Troughton RW, Richards AM, et al. . Angiotensin type-1 receptor A1166C gene polymorphism correlates with oxidative stress levels in human heart failure. Hypertension. (2006) 47:1155\u201361. 10.1161/01.HYP.0000222893.85662.cd", "ArticleIdList": ["10.1161/01.HYP.0000222893.85662.cd", "16651460"]}, {"Citation": "Urata H, Healy B, Stewart RW, Bumpus FM, Husain A. Angiotensin II-forming pathways in normal and failing human hearts. Circ Res. (1990) 66:883\u201390. 10.1161/01.RES.66.4.883", "ArticleIdList": ["10.1161/01.RES.66.4.883", "2156635"]}, {"Citation": "Andrew PJ, Mayer B. Enzymatic function of nitric oxide synthases. Cardiovasc Res. (1999) 43:521\u201331. 10.1016/S0008-6363(99)00115-7", "ArticleIdList": ["10.1016/S0008-6363(99)00115-7", "10690324"]}, {"Citation": "Landmesser U, Dikalov S, Price SR, McCann L, Fukai T, Holland SM, et al. . Oxidation of tetrahydrobiopterin leads to uncoupling of endothelial cell nitric oxide synthase in hypertension. J Clin Invest. (2003) 111:1201\u20139. 10.1172/JCI200314172", "ArticleIdList": ["10.1172/JCI200314172", "PMC152929", "12697739"]}, {"Citation": "Forstermann U, Sessa WC. Nitric oxide synthases: regulation and function. Eur Heart J. (2012) 33:829-37:37a\u221237d. 10.1093/eurheartj/ehr304", "ArticleIdList": ["10.1093/eurheartj/ehr304", "PMC3345541", "21890489"]}, {"Citation": "Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res. (2006) 71:247\u201358. 10.1016/j.cardiores.2006.05.001", "ArticleIdList": ["10.1016/j.cardiores.2006.05.001", "16765337"]}, {"Citation": "Fortuno A, Olivan S, Beloqui O, San Jose G, Moreno MU, Diez J, et al. . Association of increased phagocytic NADPH oxidase-dependent superoxide production with diminished nitric oxide generation in essential hypertension. J Hypertens. (2004) 22:2169\u201375. 10.1097/00004872-200411000-00020", "ArticleIdList": ["10.1097/00004872-200411000-00020", "15480102"]}, {"Citation": "Lirk P, Hoffmann G, Rieder J. Inducible nitric oxide synthase\u2013time for reappraisal. Curr Drug Targets Inflamm Allergy. (2002) 1:89\u2013108. 10.2174/1568010023344913", "ArticleIdList": ["10.2174/1568010023344913", "14561209"]}, {"Citation": "Schiattarella GG, Altamirano F, Tong D, French KM, Villalobos E, Kim SY, et al. . Nitrosative stress drives heart failure with preserved ejection fraction. Nature. (2019) 568:351\u20136. 10.1038/s41586-019-1100-z", "ArticleIdList": ["10.1038/s41586-019-1100-z", "PMC6635957", "30971818"]}, {"Citation": "Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. (2007) 8:519\u201329. 10.1038/nrm2199", "ArticleIdList": ["10.1038/nrm2199", "17565364"]}, {"Citation": "Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, Nie D, et al. . Endoplasmic reticulum stress plays a central role in development of leptin resistance. Cell Metab. (2009) 9:35\u201351. 10.1016/j.cmet.2008.12.004", "ArticleIdList": ["10.1016/j.cmet.2008.12.004", "19117545"]}, {"Citation": "Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E, et al. . Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science. (2004) 306:457\u201361. 10.1126/science.1103160", "ArticleIdList": ["10.1126/science.1103160", "15486293"]}, {"Citation": "Colli ML, Paula FM, Marselli L, Marchetti P, Roivainen M, Eizirik DL, et al. . Coxsackievirus B tailors the unfolded protein response to favour viral amplification in pancreatic beta cells. J Innate Immun. (2019) 11:375\u201390. 10.1159/000496034", "ArticleIdList": ["10.1159/000496034", "PMC6738210", "30799417"]}, {"Citation": "Komarova YA, Kruse K, Mehta D, Malik AB. Protein interactions at endothelial junctions and signaling mechanisms regulating endothelial permeability. Circ Res. (2017) 120:179\u2013206. 10.1161/CIRCRESAHA.116.306534", "ArticleIdList": ["10.1161/CIRCRESAHA.116.306534", "PMC5225667", "28057793"]}, {"Citation": "Othman R, Vaucher E, Couture R. Bradykinin type 1 receptor - inducible nitric oxide synthase: a new axis implicated in diabetic retinopathy. Front Pharmacol. (2019) 10:300. 10.3389/fphar.2019.00300", "ArticleIdList": ["10.3389/fphar.2019.00300", "PMC6449803", "30983997"]}, {"Citation": "Olshansky SJ, Passaro DJ, Hershow RC, Layden J, Carnes BA, Brody J, et al. . A potential decline in life expectancy in the United States in the 21st century. N Engl J Med. (2005) 352:1138\u201345. 10.1056/NEJMsr043743", "ArticleIdList": ["10.1056/NEJMsr043743", "15784668"]}, {"Citation": "Bhuiyan T, Maurer MS. Heart failure with preserved ejection fraction: persistent diagnosis, therapeutic enigma. Curr Cardiovasc Risk Rep. (2011) 5:440\u20139. 10.1007/s12170-011-0184-2", "ArticleIdList": ["10.1007/s12170-011-0184-2", "PMC3211140", "22081782"]}, {"Citation": "Sarma S, Stoller D, Hendrix J, Howden E, Lawley J, Livingston S, et al. . Mechanisms of chronotropic incompetence in heart failure with preserved ejection fraction. Circ Heart Fail. (2020) 13:e006331. 10.1161/CIRCHEARTFAILURE.119.006331", "ArticleIdList": ["10.1161/CIRCHEARTFAILURE.119.006331", "PMC7347285", "32164435"]}, {"Citation": "Borlaug BA, Olson TP, Lam CS, Flood KS, Lerman A, Johnson BD, et al. . Global cardiovascular reserve dysfunction in heart failure with preserved ejection fraction. J Am Coll Cardiol. (2010) 56:845\u201354. 10.1016/j.jacc.2010.03.077", "ArticleIdList": ["10.1016/j.jacc.2010.03.077", "PMC2950645", "20813282"]}, {"Citation": "Chirinos JA, Sweitzer N. Ventricular-arterial coupling in chronic heart failure. Cardiac Fail Rev. (2017) 3:12\u20138. 10.15420/cfr.2017:4:2", "ArticleIdList": ["10.15420/cfr.2017:4:2", "PMC5494149", "28785470"]}, {"Citation": "Borlaug BA, Kane GC, Melenovsky V, Olson TP. Abnormal right ventricular-pulmonary artery coupling with exercise in heart failure with preserved ejection fraction. Eur Heart J. (2016) 37:3293\u2013302. 10.1093/eurheartj/ehw241", "ArticleIdList": ["10.1093/eurheartj/ehw241", "PMC8483148", "27354047"]}, {"Citation": "Borlaug BA, Nishimura RA, Sorajja P, Lam CS, Redfield MM. Exercise hemodynamics enhance diagnosis of early heart failure with preserved ejection fraction. Circ Heart Fail. (2010) 3:588\u201395. 10.1161/CIRCHEARTFAILURE.109.930701", "ArticleIdList": ["10.1161/CIRCHEARTFAILURE.109.930701", "PMC3048586", "20543134"]}, {"Citation": "Shear FE. Novel paradigms in the therapeutic management of heart failure with preserved ejection fraction: clinical perspectives. Am J Cardiovasc Dis. (2019) 9:91\u2013108.", "ArticleIdList": ["PMC6872467", "31763061"]}, {"Citation": "Schwinger RHG. Pathophysiology of heart failure. Cardiovasc Diagn Ther. (2021) 11:263\u201376. 10.21037/cdt-20-302", "ArticleIdList": ["10.21037/cdt-20-302", "PMC7944197", "33708498"]}, {"Citation": "Nakato R, Ohkubo Y, Konishi A, Shibata M, Kaneko Y, Iwawaki T, et al. . Regulation of the unfolded protein response via S-nitrosylation of sensors of endoplasmic reticulum stress. Sci Rep. (2015) 5:14812. 10.1038/srep14812", "ArticleIdList": ["10.1038/srep14812", "PMC4597200", "26446798"]}, {"Citation": "Fribley AM, Miller JR, Brownell AL, Garshott DM, Zeng Q, Reist TE, et al. . Celastrol induces unfolded protein response-dependent cell death in head and neck cancer. Exp Cell Res. (2015) 330:412\u201322. 10.1016/j.yexcr.2014.08.014", "ArticleIdList": ["10.1016/j.yexcr.2014.08.014", "PMC4280347", "25139619"]}, {"Citation": "Silberman GA, Fan TH, Liu H, Jiao Z, Xiao HD, Lovelock JD, et al. . Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation. (2010) 121:519\u201328. 10.1161/CIRCULATIONAHA.109.883777", "ArticleIdList": ["10.1161/CIRCULATIONAHA.109.883777", "PMC2819317", "20083682"]}, {"Citation": "Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation. (2000) 101:2118\u201321. 10.1161/01.CIR.101.17.2118", "ArticleIdList": ["10.1161/01.CIR.101.17.2118", "10790356"]}, {"Citation": "Cosentino F, Hishikawa K, Katusic ZS, Luscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation. (1997) 96:25\u20138. 10.1161/01.CIR.96.1.25", "ArticleIdList": ["10.1161/01.CIR.96.1.25", "9236411"]}, {"Citation": "Heitzer T, Yla-Herttuala S, Luoma J, Kurz S, Munzel T, Just H, et al. . Cigarette smoking potentiates endothelial dysfunction of forearm resistance vessels in patients with hypercholesterolemia. Role of oxidized LDL. Circulation. (1996) 93:1346\u201353. 10.1161/01.CIR.93.7.1346", "ArticleIdList": ["10.1161/01.CIR.93.7.1346", "8641023"]}, {"Citation": "Maier W, Cosentino F, Lutolf RB, Fleisch M, Seiler C, Hess OM, et al. . Tetrahydrobiopterin improves endothelial function in patients with coronary artery disease. J Cardiovasc Pharmacol. (2000) 35:173\u20138. 10.1097/00005344-200002000-00001", "ArticleIdList": ["10.1097/00005344-200002000-00001", "10672847"]}, {"Citation": "Shang LL, Sanyal S, Pfahnl AE, Jiao Z, Allen J, Liu H, et al. . NF-kappaB-dependent transcriptional regulation of the cardiac scn5a sodium channel by angiotensin II. Am J Physiol Cell Physiol. (2008) 294:C372\u20139. 10.1152/ajpcell.00186.2007", "ArticleIdList": ["10.1152/ajpcell.00186.2007", "PMC3150844", "18032528"]}, {"Citation": "Sun Y. Myocardial repair/remodelling following infarction: roles of local factors. Cardiovasc Res. (2009) 81:482\u201390. 10.1093/cvr/cvn333", "ArticleIdList": ["10.1093/cvr/cvn333", "PMC2639132", "19050008"]}, {"Citation": "Kassiri Z, Zhong J, Guo D, Basu R, Wang X, Liu PP, et al. . Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail. (2009) 2:446\u201355. 10.1161/CIRCHEARTFAILURE.108.840124", "ArticleIdList": ["10.1161/CIRCHEARTFAILURE.108.840124", "19808375"]}, {"Citation": "Miguel-Carrasco JL, Zambrano S, Blanca AJ, Mate A, Vazquez CM. Captopril reduces cardiac inflammatory markers in spontaneously hypertensive rats by inactivation of NF-kB. J Inflamm. (2010) 7:21. 10.1186/1476-9255-7-21", "ArticleIdList": ["10.1186/1476-9255-7-21", "PMC2879251", "20462420"]}, {"Citation": "Liu H, Wang L, Pan Y, Wang X, Ding Y, Zhou C, et al. . Celastrol alleviates aortic valve calcification via inhibition of NADPH oxidase 2 in valvular interstitial cells. JACC Basic Transl Sci. (2020) 5:35\u201349. 10.1016/j.jacbts.2019.10.004", "ArticleIdList": ["10.1016/j.jacbts.2019.10.004", "PMC7000868", "32043019"]}, {"Citation": "Carnesecchi S, Deffert C, Pagano A, Garrido-Urbani S, Metrailler-Ruchonnet I, Schappi M, et al. . NADPH oxidase-1 plays a crucial role in hyperoxia-induced acute lung injury in mice. Am J Respir Crit Care Med. (2009) 180:972\u201381. 10.1164/rccm.200902-0296OC", "ArticleIdList": ["10.1164/rccm.200902-0296OC", "PMC2778156", "19661248"]}, {"Citation": "Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Oshima T, Chayama K. Endothelial function and oxidative stress in renovascular hypertension. N Engl J Med. (2002) 346:1954\u201362. 10.1056/NEJMoa013591", "ArticleIdList": ["10.1056/NEJMoa013591", "12075056"]}, {"Citation": "Jeong EM, Monasky MM, Gu L, Taglieri DM, Patel BG, Liu H, et al. . Tetrahydrobiopterin improves diastolic dysfunction by reversing changes in myofilament properties. J Mol Cell Cardiol. (2013) 56:44\u201354. 10.1016/j.yjmcc.2012.12.003", "ArticleIdList": ["10.1016/j.yjmcc.2012.12.003", "PMC3666585", "23247392"]}, {"Citation": "Antoniades C, Channon KM, Stefanadis C. Letter by Antoniades et al. regarding article, Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction. Circulation. (2010) 122:e558. 10.1161/CIRCULATIONAHA.110.952861", "ArticleIdList": ["10.1161/CIRCULATIONAHA.110.952861", "21098456"]}, {"Citation": "Coulibaly A, Haas A, Steinmann S, Jakobs A, Schmidt TJ, Klempnauer KH. The natural anti-tumor compound Celastrol targets a Myb-C/EBPbeta-p300 transcriptional module implicated in myeloid gene expression. PLoS ONE. (2018) 13:e0190934. 10.1371/journal.pone.0190934", "ArticleIdList": ["10.1371/journal.pone.0190934", "PMC5796697", "29394256"]}, {"Citation": "Lovelock JD, Monasky MM, Jeong EM, Lardin HA, Liu H, Patel BG, et al. . Ranolazine improves cardiac diastolic dysfunction through modulation of myofilament calcium sensitivity. Circ Res. (2012) 110:841\u201350. 10.1161/CIRCRESAHA.111.258251", "ArticleIdList": ["10.1161/CIRCRESAHA.111.258251", "PMC3314887", "22343711"]}, {"Citation": "Harris SP, Lyons RG, Bezold KL. In the thick of it: HCM-causing mutations in myosin binding proteins of the thick filament. Circ Res. (2011) 108:751\u201364. 10.1161/CIRCRESAHA.110.231670", "ArticleIdList": ["10.1161/CIRCRESAHA.110.231670", "PMC3076008", "21415409"]}, {"Citation": "Gao Y, Zhou S, Pang L, Yang J, Li HJ, Huo X, et al. . Celastrol suppresses nitric oxide synthases and the angiogenesis pathway in colorectal cancer. Free Radic Res. (2019) 53:324\u201334. 10.1080/10715762.2019.1575512", "ArticleIdList": ["10.1080/10715762.2019.1575512", "PMC6715291", "30773944"]}, {"Citation": "Brodde OE, Daul A, Michel MC, Zerkowski HR. Importance of beta 2-adrenergic receptors in heart failure. Z Kardiol. (1992) 81(Suppl. 4):71\u20138.", "ArticleIdList": ["1363262"]}, {"Citation": "Bristow MR, Hershberger RE, Port JD, Gilbert EM, Sandoval A, Rasmussen R, et al. . Beta-adrenergic pathways in nonfailing and failing human ventricular myocardium. Circulation. (1990) 82(Suppl. 2):I12\u201325.", "ArticleIdList": ["2164894"]}, {"Citation": "Hsu E, Bajaj T. Beta 2 Agonists. Treasure Island (FL): StatPearls (2020)."}, {"Citation": "Lundberg JO, Weitzberg E, Gladwin MT. The nitrate-nitrite-nitric oxide pathway in physiology and therapeutics. Nat Rev Drug Discov. (2008) 7:156\u201367. 10.1038/nrd2466", "ArticleIdList": ["10.1038/nrd2466", "18167491"]}, {"Citation": "Rassaf T, Ferdinandy P, Schulz R. Nitrite in organ protection. Br J Pharmacol. (2014) 171:1\u201311. 10.1111/bph.12291", "ArticleIdList": ["10.1111/bph.12291", "PMC3874691", "23826831"]}, {"Citation": "Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K, et al. . Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation. (1997) 96:3954\u201362. 10.1161/01.CIR.96.11.3954", "ArticleIdList": ["10.1161/01.CIR.96.11.3954", "9403620"]}, {"Citation": "Nakajima M, Hutchinson HG, Fujinaga M, Hayashida W, Morishita R, Zhang L, et al. . The angiotensin II type 2 (AT2) receptor antagonizes the growth effects of the AT1 receptor: gain-of-function study using gene transfer. Proc Natl Acad Sci U S A. (1995) 92:10663\u20137. 10.1073/pnas.92.23.10663", "ArticleIdList": ["10.1073/pnas.92.23.10663", "PMC40672", "7479861"]}, {"Citation": "Opie LH, Sack MN. Enhanced angiotensin II activity in heart failure: reevaluation of the counterregulatory hypothesis of receptor subtypes. Circ Res. (2001) 88:654\u20138. 10.1161/hh0701.089175", "ArticleIdList": ["10.1161/hh0701.089175", "11304486"]}, {"Citation": "Tsai CT, Lai LP, Kuo KT, Hwang JJ, Hsieh CS, Hsu KL, et al. . Angiotensin II activates signal transducer and activators of transcription 3 via Rac1 in atrial myocytes and fibroblasts: implication for the therapeutic effect of statin in atrial structural remodeling. Circulation. (2008) 117:344\u201355. 10.1161/CIRCULATIONAHA.107.695346", "ArticleIdList": ["10.1161/CIRCULATIONAHA.107.695346", "18172037"]}, {"Citation": "Xue XD, Huang JH, Wang HS. Angiotensin II activates signal transducers and activators of transcription 3 via Rac1 in the atrial tissue in permanent atrial fibrillation patients with rheumatic heart disease. Cell Biochem Biophys. (2015) 71:205\u201313. 10.1007/s12013-014-0186-z", "ArticleIdList": ["10.1007/s12013-014-0186-z", "25151145"]}, {"Citation": "Skoumal R, Toth M, Serpi R, Rysa J, Leskinen H, Ulvila J, et al. . Parthenolide inhibits STAT3 signaling and attenuates angiotensin II-induced left ventricular hypertrophy via modulation of fibroblast activity. J Mol Cell Cardiol. (2011) 50:634\u201341. 10.1016/j.yjmcc.2011.01.001", "ArticleIdList": ["10.1016/j.yjmcc.2011.01.001", "21223972"]}, {"Citation": "Zouein FA, Zgheib C, Hamza S, Fuseler JW, Hall JE, Soljancic A, et al. . Role of STAT3 in angiotensin II-induced hypertension and cardiac remodeling revealed by mice lacking STAT3 serine 727 phosphorylation. Hypertens Res. (2013) 36:496\u2013503. 10.1038/hr.2012.223", "ArticleIdList": ["10.1038/hr.2012.223", "PMC3674130", "23364341"]}, {"Citation": "Altara R, Harmancey R, Didion SP, Booz GW, Zouein FA. Cardiac STAT3 deficiency impairs contractility and metabolic homeostasis in hypertension. Front Pharmacol. (2016) 7:436. 10.3389/fphar.2016.00436", "ArticleIdList": ["10.3389/fphar.2016.00436", "PMC5110511", "27899891"]}, {"Citation": "Hu N, Zhang Y. TLR4 knockout attenuated high fat diet-induced cardiac dysfunction via NF-kappaB/JNK-dependent activation of autophagy. Biochim Biophys Acta Mol Basis Dis. (2017) 1863:2001\u201311. 10.1016/j.bbadis.2017.01.010", "ArticleIdList": ["10.1016/j.bbadis.2017.01.010", "28108421"]}, {"Citation": "Li HY, Zhang J, Sun LL, Li BH, Gao HL, Xie T, et al. . Celastrol induces apoptosis and autophagy via the ROS/JNK signaling pathway in human osteosarcoma cells: an in vitro and in vivo study. Cell Death Dis. (2015) 6:e1604. 10.1038/cddis.2014.543", "ArticleIdList": ["10.1038/cddis.2014.543", "PMC4669742", "25611379"]}, {"Citation": "Hou W, Liu B, Xu H. Celastrol: progresses in structure-modifications, structure-activity relationships, pharmacology and toxicology. Eur J Med Chem. (2020) 189:112081. 10.1016/j.ejmech.2020.112081", "ArticleIdList": ["10.1016/j.ejmech.2020.112081", "31991334"]}, {"Citation": "Shi J, Li J, Xu Z, Chen L, Luo R, Zhang C, et al. . Celastrol: a review of useful strategies overcoming its limitation in anticancer application. Front Pharmacol. (2020) 11:558741. 10.3389/fphar.2020.558741", "ArticleIdList": ["10.3389/fphar.2020.558741", "PMC7751759", "33364939"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "6", "Day": "15"}, {"Year": "2021", "Month": "7", "Day": "27"}, {"Year": "2021", "Month": "9", "Day": "7", "Hour": "7", "Minute": "46"}, {"Year": "2021", "Month": "9", "Day": "8", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "9", "Day": "8", "Hour": "6", "Minute": "1"}, {"Year": "2021", "Month": "1", "Day": "1"}], "PublicationStatus": "epublish", "ArticleIdList": ["34490381", "PMC8418197", "10.3389/fcvm.2021.725602"]}}], "PubmedBookArticle": []}